TABLE 1.
Relevant demographic, medical and drug therapy data of the study population.
| n = 101 | |
| Age (years) | 69 ± 13 |
| Gender, male (n, %) | 59 (58) |
| Weight (kg) | 74 ± 18 |
| Race (n, %) | |
| Caucasian | 61 (60) |
| Black African | 14 (14) |
| Northern African | 24 (24) |
| Asian | 2 (2) |
| ESKD etiology (n, %) | |
| Diabetes mellitus | 17 (17) |
| Hypertensive nephrosclerosis | 22 (22) |
| Combination of diabetic and vascular kidney failure | 23 (23) |
| Glomerulonephritis | 7 (7) |
| Tubulointerstitial nephropathy | 7 (7) |
| Genetic disease | 9 (9) |
| Other | 16 (16) |
| Dialysis vintage (months) | 33 (6–71) |
| Vascular access type (n, %) | |
| AV fistula | 41 (41) |
| AV graft | 4 (4) |
| Catheter | 56 (55) |
| History of HD vascular access dysfunction (n, %) | 33 (33) |
| Treated diabetes mellitus (n, %) | 47 (47) |
| Use of antiplatelets (n, %) | |
| None | 36 (36) |
| Acetylsalicylic acid | 52 (51) |
| Clopidogrel | 1 (1) |
| Combination | 12 (12) |
| Use of anticoagulants (n, %) | |
| None | 85 (84) |
| Anti-vitamin K | 14 (14) |
| LMWH | 2 (2) |
Data are given as mean ± SD, proportions (%) or median (IQR) when appropriate. ESKD, end-stage kidney disease; AV, arteriovenous; HD, hemodialysis; LMWH, low molecular weight heparin.
History of HD vascular access dysfunction was defined as arteriovenous fistula thrombosis ever, catheter replacement for thrombotic dysfunction ever, or urokinase use because of access thrombosis during the last 3 months.